MARKET

TAK

TAK

Takeda Pharm
NYSE
16.61
-0.02
-0.12%
After Hours: 16.61 0 0.00% 16:10 05/15 EDT
OPEN
16.69
PREV CLOSE
16.63
HIGH
16.73
LOW
16.59
VOLUME
2.79M
TURNOVER
--
52 WEEK HIGH
18.90
52 WEEK LOW
12.77
MARKET CAP
52.48B
P/E (TTM)
43.31
1D
5D
1M
3M
1Y
5Y
1D
Trump Trade: Trump says Xi agreed to buy 200 jets from Boeing
TipRanks · 15h ago
Justice Department announces $13.67M civil settlement with Takeda
TipRanks · 1d ago
Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million
Dow Jones · 1d ago
Takeda to shed 4,500 jobs as part of cost-cutting drive
Seeking Alpha · 1d ago
Keros Therapeutics posts Q1 net loss as license revenue drops
Reuters · 1d ago
UPDATE 2-US FDA approves BeOne's drug for a type of blood cancer
Reuters · 2d ago
Takeda's Next Wave Of Drugs Has Investors Watching Closely
Benzinga · 2d ago
Xenetic Biosciences' Q1 royalty revenue rises, net loss narrows
Reuters · 2d ago
More
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.

Webull offers Takeda Pharmaceutical Co Ltd (ADR) stock information, including NYSE: TAK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TAK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TAK stock methods without spending real money on the virtual paper trading platform.